Table 1.
Association of EPHA3 with clinical parameters
| Characteristics | EPHA3 expression | X 2 | P value | |
|---|---|---|---|---|
| − | + | |||
| SCLC cases (N = 61) | 40 | 21 | 10.101 | 0.001* |
| Age | 0.282 | 0.596 | ||
| ≤59 | 20 | 12 | ||
| >59 | 20 | 9 | ||
| Gender | 0.091 | 0.763 | ||
| Male | 30 | 15 | ||
| Female | 10 | 6 | ||
| Disease stage | 2.743 | 0.098 | ||
| Limited disease (LD) | 16 | 4 | ||
| Extensive disease (ED) | 24 | 17 | ||
| Survival status | 6.733 | 0.009** | ||
| Survival | 8 | 11 | ||
| Death | 32 | 10 | ||
| Normal lung tissues (N = 25) | 7 | 18 | ||
| Age | 0.198 | 0.656 | ||
| ≤59 | 4 | 12 | ||
| >59 | 3 | 6 | ||
| Gender | 0.103 | 0.748 | ||
| Male | 3 | 9 | ||
| Female | 4 | 9 | ||
The bold emphasis highlighted the comparison between the SCLC cases and normal cases
The symbol “*” pointed the result of X 2 test between the SCLC cases and normal cases. It has been displayed in the text “EPHA3 expression was detectable in 18 of 25 (72 %) normal lung tissue samples (Fig. 9a), compared with 21 of 61 (34.4 %) SCLC tumor samples (*P<0.05, X 2 test, Fig. 9b and c, Table 1)”